Independent peptide care research · United States
Peptide therapy providers and access, independently compared.
See what a clinic offers, what you would pay, and what still needs checking. Start with BPC-157 access or compare published online peptide care terms—before you book.
Free access summary and provider questions. No account or email needed.
Start with the peptide. Check the access claim.
A provider listing, a consultation, and an available prescription are not the same thing. Here is the distinction to check first.
| Peptide | What the reviewed sources establish | What to check next |
|---|---|---|
| BPC-157 | No FDA-approved BPC-157 drug. FDA’s 2026 briefing identifies neither BPC-157 free base nor acetate as an ingredient in an approved drug.Source 1 | Check the evidence behind any advertised access route before paying. Find my BPC-157 next step |
| TB-500 | No FDA-approved drug for the TB-500 fragment evaluated by FDA. The briefing distinguishes this substance from full-length thymosin beta-4.Source 2 | Check the exact substance being advertised, not just the name on the page. Find my TB-500 next step |
| Sermorelin | Compounded care is advertised. AgelessRx publishes a clinician-led sermorelin offer. That is evidence of an advertised service, not FDA approval of the compounded product.Source 3Source 4 | Confirm the formulation, dispensing pharmacy, state availability, and complete financial commitment. See the published offer below |
FDA also identifies safety uncertainties for BPC-157 and TB-500.Source 5 This page does not establish a routine U.S. dispensing route for either substance. A clinic advertisement or an advisory review is not a drug approval.Source 4Source 6
Compare online peptide therapy providers
These three examples show different booking and payment arrangements. They are listed alphabetically, not ranked, and do not represent the whole market.
Scope: We compare published service terms—not treatment effectiveness or verified access to every peptide a clinic advertises. These are not BPC-157 or TB-500 supplier recommendations.
The source links below are direct links, not affiliate tracking links. How we make money.
| Provider | Published service and payment arrangement | The detail to resolve before paying |
|---|---|---|
| AgelessRx | A prepaid subscription offer. Its compounded sermorelin page ties a $99 introductory month to a three-month plan paid upfront and lists $149/month afterward. It also describes ongoing clinician messaging.Source 3 | The introductory monthly figure is not the full upfront bill. Confirm the amount charged now, renewal schedule, and any required lab fees. Its general policy does not guarantee a refund once an order reaches the pharmacy.Source 7 |
| Defy Medical | Consultation-led care without a subscription. Its general onboarding page describes help with blood testing, a recent physical, and patient history before a telemedicine consultation. The page advertises no subscriptions or contracts.Source 8 | No complete peptide-specific total appears on that onboarding page. Ask which requirements apply, what each step costs, and what you would still owe if no prescription is written. Medication and follow-up arrangements need a specific quote.Source 8 |
| Valhalla Vitality | An advertised free consultation with no required membership. Its homepage also offers optional repeat-order subscriptions. Booking begins with an account and an eligibility check.Source 9Source 10 | A free consultation is not a free treatment plan. Confirm the exact peptide and formulation, pharmacy, state availability, medication and other required charges, and cancellation terms. The consultation offer does not establish access to a particular peptide.Source 9 |
Provider-published terms checked October 13, 2026. These are different service arrangements, not equivalent treatment packages. A missing charge is unknown—not $0.
Compare the amount due today, the next bill, and what happens if treatment is not prescribed. A lower headline price cannot answer all three questions.
A clearer next step, without handing over your inbox
Find My Peptide Path helps you organize the decision before contacting a clinic. Choose the peptide and what you want to understand. You do not need to share your medical history or contact details to see the result.
See what the access evidence supports
Get the relevant access finding, its source date, and the important unanswered questions. When an appropriate care route has not been verified, the result says so rather than inventing a provider match.
Know what to ask about an offer
See which details still need confirmation: the exact product, who provides care, who dispenses it, state coverage, required charges, and refund terms.
Leave with questions you can use
Copy a short brief for a clinician or provider. You can use it with an organization you already know; you do not have to choose a featured service.
Free to use. No account or email required. This is an information tool, not a medical evaluation or a prescription service.
Before you book, ask for the missing details
Use the same questions with every peptide clinic—including one you already trust.
Before I pay, please confirm the exact peptide and formulation you would consider, whether your clinician and dispensing pharmacy can serve my state, and the current basis for supplying that product.
Please itemize the consultation, medication, required labs, membership, shipping, and follow-up charges. What would I pay now, what renews automatically, and how do I cancel?
What would I owe if no prescription is written or the pharmacy cannot fill it? Which payments are refundable? Who handles clinical questions after the appointment?
Keep the answer tied to the exact offer. A clinic’s general policy may not settle the terms of the peptide, formulation, or plan you are considering.
What a comparison here does—and does not—mean
Sources, not a blanket “verified” badge
The access snapshot uses official FDA materials. The provider table uses the clinics’ own published pages. A provider-published statement shows what the clinic says; it is not an independent license check, pharmacy inspection, or clinical endorsement.
Prices with their conditions attached
We keep the advertised purchase unit and billing arrangement beside the price. We do not turn a consultation into a treatment total, an introductory month into a full upfront bill, or an undisclosed charge into zero.
Unanswered questions stay visible
We distinguish the published fact from the question it leaves open. Inclusion is not a safety rating, an approval guarantee, or a finding that a treatment is right for you. This page compares documents and service terms; it does not claim hands-on product testing or clinical review.
Payment does not determine the evidence we report or the alphabetical order of this comparison. Read our methodology and commercial disclosure.
About Peptide Care Index
Peptide Care Index is an independent publisher for people researching peptide care before they spend money. We begin with BPC-157 access questions and selected online care offers, separating what the sources support from what still needs checking.
We are not a clinic, pharmacy, or laboratory supplier. We do not prescribe, dispense, or decide which peptide you should use. Medical evaluation and treatment decisions belong with a qualified clinician; orders and care agreements remain with the organization you choose.
Sources and check dates
Sources below were checked October 13, 2026. The FDA briefings describe the agency’s analysis for an advisory meeting; they are not final approval decisions. Provider pages describe advertised services and policies, not independently confirmed clinical performance.
- 1
U.S. Food and Drug Administration. BPC-157 briefing for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Approval and monograph statement: printed page 9, PDF page 9. Staff evaluation dated May 11, 2026. Checked October 13, 2026.
Back to text - 2
U.S. Food and Drug Administration. TB-500 briefing for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Approval statement: printed page 7, PDF page 7. Fragment versus full-length thymosin beta-4: printed page 25, PDF page 25. Checked October 13, 2026.
Back to text - 3
AgelessRx. Sermorelin Injection. Offer, upfront-plan qualification, recurring price, and messaging terms in the “Expert care that starts with you” section. Provider-published. Checked October 13, 2026.
Back to text:ab - 4
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Compounded drugs are not FDA-approved. Checked October 13, 2026.
Back to text:ab - 5
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. BPC-157 and TB-500 entries appear in the withdrawn-nomination section of the reviewed page. Checked October 13, 2026.
Back to text - 6
U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Advisory-meeting context and materials. Checked October 13, 2026.
Back to text - 7
AgelessRx. Frequently Asked Questions. Orders: refund/cancellation policy; treatment-specific state restrictions. Provider-published. Checked October 13, 2026.
Back to text - 8
Defy Medical. Get Started. New-patient process, telemedicine, separate ordering, and no-subscription/no-contract statement. General onboarding terms, not a peptide-specific quote. Provider-published. Checked October 13, 2026.
Back to text:ab - 9
- 10
Valhalla Vitality. Book Your Consultation. Account and eligibility-check requirements for scheduling. Provider-published. Checked October 13, 2026.
Back to text